CELGENE CORPORATION
547Patents
421Active
547Granted
60Portfolio score
Filing activity: Jan 13, 1983 → Jul 3, 2024 · 84 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9101621B2 | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation | Emerging Cross-Sectional Technologies | 710 | Active |
| US5635517A | Method of reducing TNF.alpha. levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines | Emerging Cross-Sectional Technologies | 275 | Expired |
| US5698579A | Cyclic amides | Chemistry; Metallurgy | 172 | Expired |
| US5877200A | Cyclic amides | Chemistry; Metallurgy | 170 | Expired |
| US6281230A | Isoindolines, method of use, and pharmaceutical compositions | Human Necessities | 161 | Expired |
| US6316471A | Isoindolines, method of use, and pharmaceutical compositions | Human Necessities | 159 | Expired |
| US5929117A | Immunotherapeutic agents | Chemistry; Metallurgy | 154 | Expired |
| US5798368A | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNF.alpha. levels | Chemistry; Metallurgy | 153 | Expired |
| US6476052B1 | Isoindolines, method of use, and pharmaceutical compositions | Human Necessities | 149 | Expired |
| US5955476A | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels | Human Necessities | 142 | Expired |
| US6335349B1 | Substituted 2(2,6-dioxopiperidin-3-yl)isoindolines | Human Necessities | 142 | Expired |
| US6315720A | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug | Emerging Cross-Sectional Technologies | 141 | Expired |
| US5908850A | Method of treating attention deficit disorders with d-threo methylphenidate | Human Necessities | 139 | Expired |
| US6020358A | Substituted phenethylsulfones and method of reducing TNF.alpha. levels | Emerging Cross-Sectional Technologies | 136 | Expired |
| US5874448A | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNF.alpha. levels | Chemistry; Metallurgy | 136 | Expired |
| US7147626B2 | Cord blood and placenta collection kit | Human Necessities | 134 | Expired |
| US6555554B2 | Isoindolines, method of use, and pharmaceutical compositions | Emerging Cross-Sectional Technologies | 133 | Expired |
| US6380239B1 | Substituted 1-oxo- and 1,3-dioxoisoindoline and method of reducing inflammatory cytokine levels | Human Necessities | 125 | Expired |
| US5728844A | Immunotherapeutic agents | Chemistry; Metallurgy | 107 | Expired |
| US6355656B1 | Phenidate drug formulations having diminished abuse potential | Chemistry; Metallurgy | 105 | Expired |
| US7189740B2 | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes | Human Necessities | 94 | Expired |
| US7244759B2 | Isoindoline compounds and methods of making and using the same | Chemistry; Metallurgy | 93 | Expired |
| US7874984B2 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug | Emerging Cross-Sectional Technologies | 91 | Active |
| US6528530B2 | Phenidate drug formulations having diminished abuse potential | Chemistry; Metallurgy | 86 | Expired |
| US6045501A | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug | Emerging Cross-Sectional Technologies | 86 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.